$BNTC
Benitec Biopharma Inc.

2023 Q3 Form 10-K Financial Statement

#000119312523239121 Filed on September 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2023
Revenue $0.00 $10.00K $75.00K
YoY Change 2.74%
Cost Of Revenue -$106.0K $0.00
YoY Change -100.0%
Gross Profit $106.0K $80.00K
YoY Change 25.0%
Gross Profit Margin 106.67%
Selling, General & Admin $1.551M $1.370M $6.380M
YoY Change -19.22% -11.78% -4.0%
% of Gross Profit 1463.21% 7975.0%
Research & Development $4.429M $3.190M $12.77M
YoY Change 66.5% 0.44% 13.33%
% of Gross Profit 4178.3% 15967.5%
Depreciation & Amortization $19.00K $136.0K
YoY Change -54.76% -18.56%
% of Gross Profit 17.92% 170.0%
Operating Expenses $5.874M $4.560M $19.16M
YoY Change 28.25% -3.57% 6.86%
Operating Profit -$5.874M -$19.08M
YoY Change 28.25% 6.87%
Interest Expense -$6.000K -$30.00K -$33.00K
YoY Change -33.33% -89.25% 3.13%
% of Operating Profit
Other Income/Expense, Net -$80.00K -$80.00K -$481.0K
YoY Change -84.41% 60.0% 35.88%
Pretax Income -$5.954M -$4.660M -$18.95M
YoY Change 16.91% -8.03% 9.12%
Income Tax
% Of Pretax Income
Net Earnings -$6.000M -$4.660M -$19.56M
YoY Change 17.65% -8.03% 7.44%
Net Earnings / Revenue -46600.0% -26082.67%
Basic Earnings Per Share -$2.76 -$14.12
Diluted Earnings Per Share -$2.76 -$2.83 -$14.12
COMMON SHARES
Basic Shares Outstanding 2.547M 27.98M 1.386M
Diluted Shares Outstanding 2.157M 1.386M

Balance Sheet

Concept 2023 Q3 2023 Q2 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.86M $2.480M $2.480M
YoY Change 56.43% -38.95% -38.95%
Cash & Equivalents $25.90M $2.500M $2.480M
Short-Term Investments
Other Short-Term Assets $482.0K $1.184M $1.190M
YoY Change -9.23% 59.78% 57.62%
Inventory
Prepaid Expenses $565.0K $1.280M
Receivables $53.00K $60.00K $60.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $26.41M $3.729M $3.730M
YoY Change 54.63% -22.63% -22.61%
LONG-TERM ASSETS
Property, Plant & Equipment $68.00K $87.00K $610.0K
YoY Change -62.01% -60.81% -38.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $85.00K $97.00K $120.0K
YoY Change -28.57% -28.15% -25.0%
Total Long-Term Assets $641.0K $735.0K $730.0K
YoY Change -38.01% -36.25% -36.69%
TOTAL ASSETS
Total Short-Term Assets $26.41M $3.729M $3.730M
Total Long-Term Assets $641.0K $735.0K $730.0K
Total Assets $27.05M $4.464M $4.460M
YoY Change 49.34% -25.26% -25.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.528M $1.140M $1.140M
YoY Change 151.32% 170.14% 170.14%
Accrued Expenses $2.966M $2.770M $2.770M
YoY Change 30.37% 35.85% 35.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.534M $3.978M $3.980M
YoY Change 50.58% 57.11% 57.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $211.0K $280.0K $280.0K
YoY Change -57.03% -49.91% -49.91%
Total Long-Term Liabilities $211.0K $280.0K $280.0K
YoY Change -57.03% -49.91% -49.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.534M $3.978M $3.980M
Total Long-Term Liabilities $211.0K $280.0K $280.0K
Total Liabilities $4.745M $4.262M $4.260M
YoY Change 35.49% 37.88% 37.82%
SHAREHOLDERS EQUITY
Retained Earnings -$173.8M -$167.9M
YoY Change 13.31% 13.19%
Common Stock $196.9M $168.9M
YoY Change 16.69% 10.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.31M $202.0K $200.0K
YoY Change
Total Liabilities & Shareholders Equity $27.05M $4.464M $4.460M
YoY Change 49.34% -25.26% -25.33%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2023
OPERATING ACTIVITIES
Net Income -$6.000M -$4.660M -$19.56M
YoY Change 17.65% -8.03% 7.44%
Depreciation, Depletion And Amortization $19.00K $136.0K
YoY Change -54.76% -18.56%
Cash From Operating Activities -$4.600M -$4.090M -$18.00M
YoY Change 15.0% -15.76% 13.21%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $1.000K
YoY Change -100.0% -92.31%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 -$1.000K
YoY Change -100.0% -92.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $17.88M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 27.92M 0.000 16.02M
YoY Change 74.33%
NET CHANGE
Cash From Operating Activities -4.600M -4.090M -18.00M
Cash From Investing Activities 0.000 0.000 -1.000K
Cash From Financing Activities 27.92M 0.000 16.02M
Net Change In Cash 23.39M -4.090M -1.586M
YoY Change 87.53% -15.98% -89.9%
FREE CASH FLOW
Cash From Operating Activities -$4.600M -$4.090M -$18.00M
Capital Expenditures $0.00 $1.000K
Free Cash Flow -$4.090M -$18.00M
YoY Change -15.53% 13.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4620206
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001808898
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39267
CY2023 dei Entity Registrant Name
EntityRegistrantName
Benitec Biopharma Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
3940 Trust Way
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
CY2023 dei City Area Code
CityAreaCode
510
CY2023 dei Local Phone Number
LocalPhoneNumber
780-0819
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
CY2023 dei Trading Symbol
TradingSymbol
BNTC
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
4756798
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2547434
CY2023 dei Auditor Firm
AuditorFirmId
23
CY2023 dei Auditor Name
AuditorName
BAKER TILLY US, LLP
CY2023 dei Auditor Location
AuditorLocation
Mountain View, California
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2477000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4062000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2023Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
55000
CY2022Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1184000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
741000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
3729000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
4820000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
222000
CY2023Q2 us-gaap Deposit Assets
DepositAssets
25000
CY2022Q2 us-gaap Deposit Assets
DepositAssets
25000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
97000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
135000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
526000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
771000
CY2023Q2 us-gaap Assets
Assets
4464000
CY2022Q2 us-gaap Assets
Assets
5973000
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3231000
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1880000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
472000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
400000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
252000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3978000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2532000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
559000
CY2023Q2 us-gaap Liabilities
Liabilities
4262000
CY2022Q2 us-gaap Liabilities
Liabilities
3091000
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1645951
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1645951
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
480688
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
480688
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
168921000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
152454000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167889000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-148327000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-830000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1245000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
202000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2882000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4464000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5973000
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
75000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
73000
CY2023 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
0
CY2022 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
9000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12774000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11272000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6382000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6646000
CY2023 us-gaap Operating Expenses
OperatingExpenses
19156000
CY2022 us-gaap Operating Expenses
OperatingExpenses
17927000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-19081000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-17854000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-415000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-232000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-33000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-32000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-79000
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3000
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-11000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-481000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-354000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18208000
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
415000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
210000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
415000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
210000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19147000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17998000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18208000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.12
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.12
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-37.88
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-37.88
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1385818
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1385818
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
480688
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
480688
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
20010000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
870000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
210000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18208000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2882000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1869000
CY2023 bntc Issuance And Exercise Of Prefunded And Common Warrants Net Of Transaction Costs
IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
16015000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
452000
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
415000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
202000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18208000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
136000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
167000
CY2023 bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
245000
CY2022 bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
225000
CY2023 bntc Unrealized Gain Loss On Investment
UnrealizedGainLossOnInvestment
-3000
CY2022 bntc Unrealized Gain Loss On Investment
UnrealizedGainLossOnInvestment
-10000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
452000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
870000
CY2023 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
50000
CY2022 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
414000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-62000
CY2023 bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
1357000
CY2022 bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
1090000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
73000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
80000
CY2023 bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-252000
CY2022 bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-196000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18012000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15899000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17884000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1869000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16015000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
412000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
204000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1586000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15708000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4076000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19784000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2490000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4076000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2477000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4062000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2490000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4076000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
794000
CY2023 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-11-22
CY2023 bntc Average Foreign Exchange Rate For The Period
AverageForeignExchangeRateForThePeriod
0.673
CY2022 bntc Average Foreign Exchange Rate For The Period
AverageForeignExchangeRateForThePeriod
0.7254
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
135000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1184000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. </div>
CY2023Q2 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.6639
CY2022Q2 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.6891
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Risk </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div>
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
97000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2456032
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
49716
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19600000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18200000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18000000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15900000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2500000
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
75000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
73000
CY2023Q2 us-gaap Due From Banks
DueFromBanks
2477000
CY2022Q2 us-gaap Due From Banks
DueFromBanks
4062000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2490000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
4076000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1280000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
871000
CY2023Q2 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2022Q2 bntc Market Value Of Listed Shares
MarketValueOfListedShares
5000
CY2023Q2 us-gaap Other Assets
OtherAssets
1281000
CY2022Q2 us-gaap Other Assets
OtherAssets
876000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
741000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1405000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1404000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1318000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1182000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
222000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
136000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
167000
CY2023Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1140000
CY2022Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
422000
CY2023Q2 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
109000
CY2022Q2 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
120000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
131000
CY2023Q2 bntc Accrued Opmd Project Costs Current
AccruedOpmdProjectCostsCurrent
-1750000
CY2022Q2 bntc Accrued Opmd Project Costs Current
AccruedOpmdProjectCostsCurrent
-1089000
CY2023Q2 bntc Accrued Consultant Fees Current
AccruedConsultantFeesCurrent
88000
CY2022Q2 bntc Accrued Consultant Fees Current
AccruedConsultantFeesCurrent
47000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
69000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
71000
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3231000
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1880000
CY2022 bntc Operating Lease Right Of Use Asset Remasurement During The Period
OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod
794000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
225000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
771000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
245000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
526000
CY2022 bntc Remeasurement Of Lease Liabilities During The Period
RemeasurementOfLeaseLiabilitiesDuringThePeriod
794000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
196000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
811000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
252000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
559000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275000
CY2023Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y11M15D
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0467
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
295000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
291000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
586000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
27000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
559000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.22
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2348039
CY2023Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
234000
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6300
CY2022Q2 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
178.5
CY2023 bntc Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
127743
CY2023 bntc Weightedaverageexercisepriceofclassofwarrantsorrightsexercised
Weightedaverageexercisepriceofclassofwarrantsorrightsexercised
0.0017
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2348039
CY2023Q2 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
8.86
CY2023 bntc Class Of Warrants Or Rights Excercisable
ClassOfWarrantsOrRightsExcercisable
2348039
CY2023 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Excercisable
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable
8.86
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.34
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
44.2
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.156
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.221
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0396
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0136
CY2022Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
250000
CY2023Q2 bntc Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
3070000
CY2023Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22293000
CY2022Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18321000
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21923000
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17965000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
452000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
870000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
350000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
522000
CY2021 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
34000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
34000
CY2022 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
34000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-18953000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17369000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-609000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-839000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18208000
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18388000
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17348000
CY2023Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
221000
CY2022Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
348000
CY2023Q2 bntc Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
117000
CY2022Q2 bntc Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
170000
CY2023Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
263000
CY2022Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
205000
CY2023Q2 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
111000
CY2022Q2 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
162000
CY2023Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
15000
CY2022Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
43000
CY2023Q2 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
244000
CY2022Q2 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
151000
CY2023Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
370000
CY2022Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
356000
CY2023Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3958000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 bntc Effective Income Tax Reconciliation Percentage Permanent Differences
EffectiveIncomeTaxReconciliationPercentagePermanentDifferences
-0.0001
CY2022 bntc Effective Income Tax Reconciliation Percentage Permanent Differences
EffectiveIncomeTaxReconciliationPercentagePermanentDifferences
-0.0022
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.0019
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.0036
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2092
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2055
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0012
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0013
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-19562000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18208000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1385818
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1385818
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
480688
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
480688
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.12
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.12
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-37.88
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-37.88
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.22

Files In Submission

Name View Source Status
0001193125-23-239121-index-headers.html Edgar Link pending
0001193125-23-239121-index.html Edgar Link pending
0001193125-23-239121.txt Edgar Link pending
0001193125-23-239121-xbrl.zip Edgar Link pending
bntc-20230630.xsd Edgar Link pending
d549728d10k.htm Edgar Link pending
d549728dex21.htm Edgar Link pending
d549728dex231.htm Edgar Link pending
d549728dex311.htm Edgar Link pending
d549728dex312.htm Edgar Link pending
d549728dex321.htm Edgar Link pending
d549728dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g549728g07a03.jpg Edgar Link pending
g549728g09b03.jpg Edgar Link pending
g549728g11c03.jpg Edgar Link pending
g549728g12d03.jpg Edgar Link pending
g549728g13e03.jpg Edgar Link pending
g549728g14f03.jpg Edgar Link pending
g549728g15g03.jpg Edgar Link pending
g549728g15h04.jpg Edgar Link pending
g549728g16p01.jpg Edgar Link pending
g549728g16p02.jpg Edgar Link pending
g549728g18p03.jpg Edgar Link pending
g549728g19p04.jpg Edgar Link pending
g549728g20p05.jpg Edgar Link pending
g549728g21p06.jpg Edgar Link pending
g549728g22p07.jpg Edgar Link pending
g549728g23p08.jpg Edgar Link pending
g549728g28p24.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
bntc-20230630_def.xml Edgar Link unprocessable
bntc-20230630_pre.xml Edgar Link unprocessable
bntc-20230630_cal.xml Edgar Link unprocessable
bntc-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d549728d10k_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending